Covance Expands Global Biologics Capabilities
Mar 25, 2014
Company News Release
Covance Inc. (NYSE: CVD), one of the world’s largest and most comprehensive drug development services companies, today announced that it is building on its expertise in biologics development with new investments to meet growing client demand, including the expansion of its global bioanalytical footprint and the addition of scientific leaders to its biologics team.
An important step to continually deepen the company’s biologics capabilities is the expansion of its large molecule bioanalytical space co-located with Covance’s central laboratory facility in Indianapolis, Ind. The expansion, which is planned to open during the second half of 2014, is doubling the company’s large molecule capacity and is expected to add approximately 100 new positions over the next five years. This investment will enable Covance to further leverage its small and large molecule bioanalytical expertise while providing scientific, logistic, and regulatory synergies for our clients.
“Our new biologics solutions will enable us to work in closer collaboration with our clients, providing them actionable insights to help expedite their large molecule development,” said Deborah Keller, Executive Vice President, R&D Laboratories, Covance. “Doubling our large molecule capacity and enhancing a leading team with additional dedicated scientific experts with proven success in managing through these complexities will further strengthen our leadership position in a growing market.”
As part of the ongoing investment in biologics, the company also appointed Mike Holsapple, Ph.D., as Covance’s Executive Director of Global Immunotoxicology. Dr. Holsapple is a Fellow in the Academy of Toxicological Sciences (ATS) and past President of the Society of Toxicology bringing more than 30 years of experience in this important field. In conjunction with this appointment, Covance has launched molecule management teams of experienced scientific leaders who work closely with our clients to develop and implement tailored solutions for the development of their biologics which will leverage Covance’s broad portfolio of services, including discovery, preclinical, early and late clinical, central laboratories and commercialization.